Savara Inc
SVRA2.570USD
-0.020-0.77%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
443.85MCap. mercado
PérdidaP/E TTM
Más Datos de Savara Inc Compañía
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Información de la empresa
Símbolo de cotizaciónSVRA
Nombre de la empresaSavara Inc
Fecha de salida a bolsaJun 25, 2001
Director ejecutivoMr. Matthew (Matt) Pauls, J.D.
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección6836 Bee Cave Road
CiudadAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78746
Teléfono151285113796
Sitio Webhttps://savarapharma.com/
Símbolo de cotizaciónSVRA
Fecha de salida a bolsaJun 25, 2001
Director ejecutivoMr. Matthew (Matt) Pauls, J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
Accionistas
Accionistas
Proporción
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
33.05%
Venture Capital
22.55%
Hedge Fund
19.34%
Investment Advisor/Hedge Fund
16.33%
Private Equity
6.63%
Corporation
2.71%
Individual Investor
2.67%
Research Firm
1.67%
Bank and Trust
0.25%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
294
182.03M
105.32%
-6.77M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
2023Q1
166
87.31M
76.55%
-5.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
+3.04M
+20.84%
Mar 31, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
+2.80M
+32.35%
Mar 31, 2025
Vestal Point Capital, LP
11.00M
6.36%
+225.00K
+2.09%
Mar 31, 2025
VR Adviser, LLC
3.26M
1.88%
+3.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.71M
5.04%
+229.91K
+2.71%
Mar 31, 2025
The Vanguard Group, Inc.
8.10M
4.69%
-190.72K
-2.30%
Mar 31, 2025
Nantahala Capital Management, LLC
8.08M
4.67%
+550.12K
+7.31%
Mar 31, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Texas Capital Texas Small Cap Equity Index ETF
0.39%
iShares Micro-Cap ETF
0.07%
Texas Capital Texas Equity Index ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
iShares Biotechnology ETF
0.02%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.91%
Texas Capital Texas Small Cap Equity Index ETF
Proporción0.39%
iShares Micro-Cap ETF
Proporción0.07%
Texas Capital Texas Equity Index ETF
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporción0.04%
Nuveen ESG Small-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
